HWM

Summary

We rate HWM Overweight at ~$278.88. The short-term distribution signals (price below VWMA and 10-day EMA, negative/expanding MACD histogram, RSI falling from 66 to ~49) and defensive options positioning (put/call >1.2, elevated IV) argue the pullback may not be complete, so we would not chase at current levels. However, the long-term uptrend (price above the 50-day and 200-day SMAs) remains intact, and the fundamental catalyst is real, which supports a positive lean. Maintain existing positions with tightened stops near 268 (below the 270 support, ~1.25x ATR of 8.66). Entry triggers: (1) a confirmed bullish reversal off the 270–274 support zone with RSI turning up on expanding volume, or (2) a decisive break above the 10-day EMA/VWMA around 282–285 on strong volume. A break below 270 invalidates the medium-term setup and points to the 200-day SMA near 240. Time horizon: 5–20 trading days; reassess at next earnings for acquisition integration and gas-turbine demand signals.

The case

HWM is a best-in-class operator with genuine fundamental momentum: 24% revenue growth, gross margin expansion to 37.3%, strong FCF, raised full-year guidance, and a $150M increase in customer advances/progress payments — a leading demand indicator that deserves full weight. The clean Q2 (minimal unusual items) supports the PEG-0.8 undervaluation argument.

The valuation and leverage, however, demand respect. The stock trades at 60x trailing earnings and 19.5x book with negative tangible book value — no margin of safety. The $1.8B debt-financed acquisition pushed net debt to $3.9B, adding leverage at a possible cyclical peak. Short-term technicals confirm distribution, and the options market is defensively positioned. The technical reset is overstated (RSI at 48.82 is a sharp decline, not a healthy reset), while acquisition risk is somewhat overstated (management raised guidance post-deal, implying visible synergies).

Our analysis sharpens but does not overturn the independent read. The long-term uptrend (price above 50-day and 200-day SMAs) is intact, so we are not selling. Valuation is stretched and leverage is elevated, but the earnings beat-and-raise is a verifiable catalyst and the order-book strength is real. On balance, the fundamental catalyst outweighs the short-term technical weakness, supporting an Overweight stance at $278.88 — a great company whose fresh catalyst justifies a positive lean despite a price that already reflects substantial good news.

What would weaken it

• 60x trailing earnings and 19.5x book with negative tangible book value
• $1.8B debt-financed acquisition pushed net debt to $3.9B
• Short-term distribution signals and defensive options positioning